Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
For more information on Nouscom, please visit the company’s website at www.nouscom.com
Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
For more information on Nouscom, please visit the company’s website at www.nouscom.com
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $135.77M
Investors 5
| Date | Name | Website |
| - | Panakes Pa... | panakes.it |
| - | 5AM Ventur... | 5amventure... |
| - | Andera Par... | anderapart... |
| - | Abingworth... | abingworth... |
| - | Life Scien... | lspvc.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.11.2023 | Series C | $73.43M | - |
| 06.11.2017 | Series B | $48.77M | 5AM Ventur... |
| 17.05.2016 | Series A | $13.57M | - |
Mentions in press and media 31
| Date | Title | Description |
| 23.07.2024 | Erfahrene Expertinnen und Experten verstärken Startup-Management | Das EHT-Spin-off Riverkin begrüsst mit Nitin Kumar and Marco Adriano Magno zwei neue Mitgründer. Nitin Kumar hat einen Doktortitel in Computational Biology und war an einigen erfolgreichen Startup-Exits beteiligt. Mit diesen Erfahrungen kö... |
| 26.03.2024 | Nouscom secures additional funding from Angelini Ventures | Based in Basel, Nouscom is a clinical stage immune-oncology company developing off-the-shelf and personalized cancer vaccines based on its proprietary viral vector platform, which has the capacity to encode for large payloads of neoantigen... |
| 21.03.2024 | Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vacc... | - |
| 21.12.2023 | INDACO VENTURE PARTNERS – NOUSCOM RAISES €67.5 MILLION ($72 MILLION) IN OVERSUBSCRIBED SERIES C FINANCING ROUND | |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 14.11.2023 | Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom | Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf ... |
| 14.11.2023 | Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round | - |
| 14.11.2023 | Nouscom raises CHF65 million in oversubscribed Series C financing round | |
| 14.11.2023 | Nouscom Raises €67.5m in Series C Financing | Nouscom, a Basel, Switzerland-based clinical stage immuno-oncology company, raised €67.5M in Series C funding. The round was led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation P... |
| 09.01.2023 | Nouscom and MSD sign a clinical trial and supply agreement |
Show more